BioCentury | Jul 31, 2015
Financial News

vTv falls after $117.2M IPO

...from FDA to treat AD. Pfizer Inc. (NYSE:PFE) had licensed azeliragon from vTv predecessor company TransTech...
BioCentury | Jun 1, 2015
Clinical News

Azeliragon: Phase III started

...vTv (formerly TransTech Pharma LLC ) began the double-blind, placebo-controlled, North American Phase III trial to evaluate 5...
BioCentury | Mar 16, 2015
Company News

TransTech, Calithera Biosciences deal

...rights to develop and commercialize a portfolio of preclinical small molecule hexokinase 2 (HK2) inhibitors. TransTech...
...over expressed in many cancers and has been linked to more aggressive and invasive tumors. TransTech Pharma LLC...
BioCentury | Jul 28, 2014
Clinical News

TTP488: SPA received

...trial by year end. TTP488 has Fast Track designation In the U.S. to treat AD. TransTech...
...modulate RAGE. TransTech said Pfizer terminated the deal in 3Q11 (see BioCentury, Sept. 25, 2006). TransTech Pharma LLC...
BioCentury | Apr 21, 2014
Company News

TransTech management update

...Holcombe to president of TransTech and affiliate company High Point Pharmaceuticals LLC from SVP of TransTech...
...remaining CFO of TransTech; he succeeds Adnan Mjalli, who resigned as president and CEO of TransTech...
BioCentury | Mar 10, 2014
Product Development

Inactivating warheads

...companies have programs in Phase II trials that target PTP-1B to treat Type II diabetes. TransTech...
...Jupiter, Fla. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Targanox Inc. , Cambridge, Mass. TransTech...
BioCentury | Nov 21, 2013
Cover Story

Glucokinase alternative

...PF-04937319 Phase II Roche HMS5552 (formerly RO5305552) Phase I Teijin Pharma Ltd. TMG-123 Phase I TransTech...
BioCentury | Aug 22, 2013
Cover Story

Deep pockets

...plc have a small molecule CRHR1 antagonist in Phase II testing for various neurological indications. TransTech...
...Jolla, Calif. Shanghai Institute of Materia Medica , Shanghai, China Stanford University , Stanford, Calif. TransTech...
BioCentury | Aug 19, 2013
Clinical News

TTP399: Phase IIa data

...of <=6.5% in 85% of patients. No patients in the placebo group achieved HbA1c <=6.5%. TransTech...
...returned exclusive, worldwide rights to develop and commercialize TransTech's GKA program, including lead compound TTP399. TransTech...
...BioCentury, June 14, 2010). TransTech said it plans to identify another partner for the program. TransTech...
BioCentury | Aug 14, 2013
Clinical News

TransTech reports Phase II diabetes data for GKA compound

...NYSE:FRX) conducted the trial, which enrolled 128 Type II diabetics on stable doses of metformin. TransTech...
...returned exclusive, worldwide rights to develop and commercialize TransTech's GKA program, including lead compound TTP399. TransTech...
Items per page:
1 - 10 of 68
BioCentury | Jul 31, 2015
Financial News

vTv falls after $117.2M IPO

...from FDA to treat AD. Pfizer Inc. (NYSE:PFE) had licensed azeliragon from vTv predecessor company TransTech...
BioCentury | Jun 1, 2015
Clinical News

Azeliragon: Phase III started

...vTv (formerly TransTech Pharma LLC ) began the double-blind, placebo-controlled, North American Phase III trial to evaluate 5...
BioCentury | Mar 16, 2015
Company News

TransTech, Calithera Biosciences deal

...rights to develop and commercialize a portfolio of preclinical small molecule hexokinase 2 (HK2) inhibitors. TransTech...
...over expressed in many cancers and has been linked to more aggressive and invasive tumors. TransTech Pharma LLC...
BioCentury | Jul 28, 2014
Clinical News

TTP488: SPA received

...trial by year end. TTP488 has Fast Track designation In the U.S. to treat AD. TransTech...
...modulate RAGE. TransTech said Pfizer terminated the deal in 3Q11 (see BioCentury, Sept. 25, 2006). TransTech Pharma LLC...
BioCentury | Apr 21, 2014
Company News

TransTech management update

...Holcombe to president of TransTech and affiliate company High Point Pharmaceuticals LLC from SVP of TransTech...
...remaining CFO of TransTech; he succeeds Adnan Mjalli, who resigned as president and CEO of TransTech...
BioCentury | Mar 10, 2014
Product Development

Inactivating warheads

...companies have programs in Phase II trials that target PTP-1B to treat Type II diabetes. TransTech...
...Jupiter, Fla. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Targanox Inc. , Cambridge, Mass. TransTech...
BioCentury | Nov 21, 2013
Cover Story

Glucokinase alternative

...PF-04937319 Phase II Roche HMS5552 (formerly RO5305552) Phase I Teijin Pharma Ltd. TMG-123 Phase I TransTech...
BioCentury | Aug 22, 2013
Cover Story

Deep pockets

...plc have a small molecule CRHR1 antagonist in Phase II testing for various neurological indications. TransTech...
...Jolla, Calif. Shanghai Institute of Materia Medica , Shanghai, China Stanford University , Stanford, Calif. TransTech...
BioCentury | Aug 19, 2013
Clinical News

TTP399: Phase IIa data

...of <=6.5% in 85% of patients. No patients in the placebo group achieved HbA1c <=6.5%. TransTech...
...returned exclusive, worldwide rights to develop and commercialize TransTech's GKA program, including lead compound TTP399. TransTech...
...BioCentury, June 14, 2010). TransTech said it plans to identify another partner for the program. TransTech...
BioCentury | Aug 14, 2013
Clinical News

TransTech reports Phase II diabetes data for GKA compound

...NYSE:FRX) conducted the trial, which enrolled 128 Type II diabetics on stable doses of metformin. TransTech...
...returned exclusive, worldwide rights to develop and commercialize TransTech's GKA program, including lead compound TTP399. TransTech...
Items per page:
1 - 10 of 68